NTGN -15% on phase-1 NEO-PV-1 data at ESMO: https://globenewswire.com/news-release/2018/10/22/1624508/0/en/Neon-Therapeutics-Presents-Data-from-Ongoing-Phase-1b-NT-001-Clinical-Trial-at-European-Society-for-Medical-Oncology-2018-Congress.html There was a CC (36 minutes) earlier this morning with two slides sets: https://ir.neontherapeutics.com/static-files/07079aff-c9ce-4f54-b806-dc0e040c4884 https://ir.neontherapeutics.com/static-files/9a87ca8c-5cca-4b68-a2f4-17a499824742 Note: All patients in this trial received Opdivo in addition to NEO-PV-1 (NTGN's neoantigen vaccine).